NRC Brachytherapy Regs Go Beyond FDA To Restrict Physician Off-Label Use
This article was originally published in The Gray Sheet
Executive Summary
The Nuclear Regulatory Commission's involvement in the regulation of vascular brachytherapy devices will restrict off-label use by physicians to investigational device exemption research and procedures cleared by the agency for compassionate use.
You may also be interested in...
NRC Brachytherapy Licensing Modifications Give Doctors More Flexibility
A revised Nuclear Regulatory Commission guidance for intravascular radiation therapy goes beyond an earlier guidance by allowing "source stepping" and by permitting radiation oncologists to prescribe the two currently approved brachytherapy systems, Cordis' Checkmate and Novoste's BetaCath, without being physically present during the procedure.
NRC Brachytherapy Licensing Modifications Give Doctors More Flexibility
A revised Nuclear Regulatory Commission guidance for intravascular radiation therapy goes beyond an earlier guidance by allowing "source stepping" and by permitting radiation oncologists to prescribe the two currently approved brachytherapy systems, Cordis' Checkmate and Novoste's BetaCath, without being physically present during the procedure.
SVG Potential Indication Could Bring A Glow To Brachytherapy Contender
The solid beta radiation source balloon technology employed by Radiance Medical Systems' RDX radiation delivery catheter will present an advantage over competing intravascular brachytherapy systems in treating restenotic saphenous vein grafts (SVG), according to the Irvine, California firm.